Coronavirus Disease 2019 (COVID-19) Clinical Trials – Overview, Landscape, Trial using Vaccines vs. Therapeutics,and Trials Impacted by COVID-19

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The purpose of this report is to provide insight into the overall clinical trial landscape for COVID-19 clinical trials, trials using vaccines vs. therapeutics, and trials impacted by COVID-19.

Scope

The clinical trials data used for these analyses were extracted from GlobalData’s Clinical Trials Database. The data included clinical trials that were captured in the database as of April 22, 2021. The trials were analyzed and segmented by all COVID-19 trials, trials using vaccines, trials using therapeutics, and non-COVID-19 trials impacted due to the pandemic. Further analysis was conducted based on multinational vs. single country, clinical trial sites, status, primary endpoint status, terminated trials, phase, sponsor type, and upcoming milestone events.

Reasons to Buy

Understand the global COVID-19 landscape

The trends of vaccine COVID-19 clinical trials

The trends of therapeutic COVID-19 clinical trials

A closer look at the impact of the pandemic on non-COVID-19 trials

Table of Contents

Executive Summary

Introduction

Analysis of COVID-19 Clinical Trials

COVID-19 Clinical Trials for Vaccines

COVID-19 Clinical Trials for Therapeutics

Impact of COVID-19 on Clinical Trials

Key Findings

Appendix

Table

List of Tables

Table 1: Top Countries with COVID-19 Key Stats

Figures

List of Figures

Figure 1: Impact of COVID-19

Figure 2: Top Countries in COVID-19 Key Stats

Figure 3: Landscape of Pipeline Candidates for COVID-19, by Phase

Figure 4: Landscape of Vaccines Candidates for COVID-19, by Phase

Figure 5: Number of COVID-19 Clinical Trials by Start Date, by Month

Figure 6: Number of COVID-19 Clinical Trials, by Multinational vs. Single Country

Figure 7: Single Country COVID-19 Clinical Trials, By Region & Phase

Figure 8: Multinational Country COVID-19 Clinical Trials, By Region & Phase

Figure 9: COVID-19 Clinical Trial Sites, by Region

Figures 10 & 11: COVID-19 Clinical Trial Sites, by Country & State

Figures 12 & 13: Number of COVID-19 Clinical Trials, by Phase & Status

Figure 14: Endpoint Status for Completed COVID-19 Clinical Trials

Figure 15: Top Reasons for Terminated Trials, by Phase

Figure 16: Top Reason for Terminated Trials, by Sponsor Type

Figure 17: COVID-19 Clinical Trials by Vaccine, by Month

Figures 18 & 19: Vaccine COVID-19 Clinical Trials, by Phase & Status

Figure 20: Vaccine COVID-19 Clinical Trials, by Sponsor Type

Figure 21: Top Industry Sponsors for COVID-19 Vaccine Clinical Trials

Figure 22: Top Non-Industry Sponsors for COVID-19 Vaccine Clinical Trials

Figures 23 & 24: Pfizer/BioNTech’s Tozinameran (Comirnaty), by Status & Phase

Figures 25 & 26: Moderna’s mRNA-1273, by Status & Phase

Figures 27 & 28: Johnson & Johnson’s JNJ-78436735, by Status & Phase

Figures 29 & 30: AstraZeneca’s Covishield (Vaxzevria), by Status & Phase

Figures 31 & 32: Bharat Biotech’s Covaxin, by Status & Phase

Figures 33 & 34: CanSino Biologics’ Convidecia, by Status & Phase

Figures 35 & 36: SinoVac Biotech’s CoronaVac, by Status & Phase

Figure 37: Upcoming Filings and Regulatory Approvals for COVID-19 Vaccines

Figure 38: Clinical Trial Start Date to First Approval for Vaccines

Figure 39: COVID-19 Therapeutic Clinical Trials, by Month

Figure 40 & 41: Therapeutic COVID-19 Clinical Trials, by Phase & Status

Figure 42: Therapeutic COVID-19 Clinical Trials, by Sponsor Type

Figure 43: Top Industry Sponsors for COVID-19 Therapeutic Clinical Trials

Figure 44: Top Non-Industry Sponsors for COVID-19 Therapeutic Clinical Trials

Figures 45 & 46: Gilead Sciences’ Remdesivir (Veklury), by Status & Phase

Figures 47 & 48: Fujifim Toyama Chemical’s Favipiravir, by Status & Phase

Figures 49 & 50: Eli Lilly’s Bamlanivimab, by Status & Phase

Figures 51 & 52: Regeneron’s Casirivimab + Imdevimab, by Status & Phase

Figures 53 & 54: Eli Lilly’s Baricitinib, by Status & Phase

Figures 55 & 56: CytoDyn’s Leronlimab, by Status & Phase

Figure 57: Upcoming Filings and Regulatory Approvals for Therapeutic COVID-19 Drugs

Figure 58: Clinical Trials Disrupted Due to COVID-19

Figures 59 & 60: Disrupted Clinical Trials, by Reason

Figure 61 & 62: Disrupted Clinical Trials, by Therapy Area

Figure 63: Disrupted Clinical Trials Activities

Figure 64: Disrupted Clinical Trials, by Top Sponsors

Figure 65: Resumed Clinical Trials, by Top Five Therapy Areas

Frequently asked questions

Coronavirus Disease 2019 (COVID-19) Clinical Trials – Overview, Landscape, Trial using Vaccines vs. Therapeutics,and Trials Impacted by COVID-19 thematic reports
Currency USD
$695

Can be used by individual purchaser only

$2,085

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Coronavirus Disease 2019 (COVID-19) Clinical Trials – Overview, Landscape, Trial using Vaccines vs. Therapeutics,and Trials Impacted by COVID-19 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Coronavirus Disease 2019 (COVID-19) Clinical Trials – Overview, Landscape, Trial using Vaccines vs. Therapeutics,and Trials Impacted by COVID-19 in real time.

  • Access a live Coronavirus Disease 2019 (COVID-19) Clinical Trials – Overview, Landscape, Trial using Vaccines vs. Therapeutics,and Trials Impacted by COVID-19 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.